Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth

Mirum Pharmaceuticals

04/11/2025 21:09

Overview

Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln

Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year

Mirum updates 2025 revenue guidance to $500-$510 mln

Outlook

Mirum updates 2025 revenue guidance to $500-$510 mln

Company expects VISTAS study topline data in Q2 2026

Mirum anticipates VANTAGE study data in first half of 2027

Result Drivers

LIVMARLI SALES - LIVMARLI net product sales grew 56% over Q3 2024, contributing significantly to overall revenue growth

BILE ACID MEDICINES - Bile Acid Medicines sales increased 31% over Q3 2024, supporting revenue growth

PIPELINE PROGRESS - Enrollment completed for VISTAS PSC study, with topline data expected in Q2 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$133.01 mln
Q3 EPS
$0.05
Q3 Net Income
$2.90 mln
Q3 Operating Expenses
$130.40 mln
Q3 Operating Income
$2.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $81.50, about 13.1% above its November 3 closing price of $70.85

Press Release: ID:nBw9wwnwga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)